Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human BAY 2927088 in EGFR/HER2-mutated advanced NSCLC
jRCT2031220233Phase 1Recruiting
- Sponsor
- Bayer
- Start
- Aug 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of sevabertinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Bayer. Started Aug 2022; status: recruiting.
02
Drugs
sevabertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031220233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220233.